Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice.

Nature medicine | 2016

The transplantation of glucose-responsive, insulin-producing cells offers the potential for restoring glycemic control in individuals with diabetes. Pancreas transplantation and the infusion of cadaveric islets are currently implemented clinically, but these approaches are limited by the adverse effects of immunosuppressive therapy over the lifetime of the recipient and the limited supply of donor tissue. The latter concern may be addressed by recently described glucose-responsive mature beta cells that are derived from human embryonic stem cells (referred to as SC-β cells), which may represent an unlimited source of human cells for pancreas replacement therapy. Strategies to address the immunosuppression concerns include immunoisolation of insulin-producing cells with porous biomaterials that function as an immune barrier. However, clinical implementation has been challenging because of host immune responses to the implant materials. Here we report the first long-term glycemic correction of a diabetic, immunocompetent animal model using human SC-β cells. SC-β cells were encapsulated with alginate derivatives capable of mitigating foreign-body responses in vivo and implanted into the intraperitoneal space of C57BL/6J mice treated with streptozotocin, which is an animal model for chemically induced type 1 diabetes. These implants induced glycemic correction without any immunosuppression until their removal at 174 d after implantation. Human C-peptide concentrations and in vivo glucose responsiveness demonstrated therapeutically relevant glycemic control. Implants retrieved after 174 d contained viable insulin-producing cells.

Pubmed ID: 26808346 RIS Download

Associated grants

  • Agency: NIDCR NIH HHS, United States
    Id: DE013023
  • Agency: NIDDK NIH HHS, United States
    Id: UC4 DK104218
  • Agency: NIBIB NIH HHS, United States
    Id: R01 EB000244
  • Agency: NCI NIH HHS, United States
    Id: U54 CA151884
  • Agency: NIDDK NIH HHS, United States
    Id: UC4DK104218
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK036836
  • Agency: NIDCR NIH HHS, United States
    Id: R01 DE013023
  • Agency: NIBIB NIH HHS, United States
    Id: EB000351
  • Agency: Howard Hughes Medical Institute, United States
  • Agency: NCI NIH HHS, United States
    Id: CA151884
  • Agency: NIBIB NIH HHS, United States
    Id: R37 EB000244
  • Agency: NIBIB NIH HHS, United States
    Id: R01 EB000351
  • Agency: NIBIB NIH HHS, United States
    Id: EB000244

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


BioLegend (tool)

RRID:SCR_001134

Commercial antibody supplier and developer for biomedical research. These products are compatible with use in flow cytometry and mass cytometry, immunoprecipitation and chip, western blotting, immunofluorescence microscopy, and quantitative multiplexing.

View all literature mentions

Jackson Laboratory (tool)

RRID:SCR_004633

An independent, nonprofit organization focused on mammalian genetics research to advance human health. Their mission is to discover the genetic basis for preventing, treating, and curing human disease, and to enable research for the global biomedical community. Jackson Laboratory breeds and manages colonies of mice as resources for other research institutions and laboratories, along with providing software and techniques. Jackson Lab also conducts genetic research and provides educational material for various educational levels.

View all literature mentions

Joslin Diabetes Center Bioinformatics and Biostatistics Core (tool)

RRID:SCR_015092

Core that offers support for data-driven projects related to basic, clinical and translational research, with a particular emphasis on diabetes. The core aims to ensure that researchers take advantage of the most modern and robust methods available in the field of Bioinformatics and Biostatistics.

View all literature mentions

Joslin Diabetes Center Flow Cytometry Core Facility (tool)

RRID:SCR_009878

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides cell sorting and flow cytometry services. Specific services include cell analysis, large object sorting,magnetic cell enrichment, and automatic cell counting.

View all literature mentions

Joslin Diabetes Center Advanced Microscopy Core Facility (tool)

RRID:SCR_009875

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for performing specific morphological procedures, providing training and access to equipment, maintaining the specialized microscopes, and giving advice and interpretation.

View all literature mentions

Joslin Diabetes Center Animal Physiology Core Facility (tool)

RRID:SCR_009876

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides technically advanced physiological evaluation of metabolism in diabetes, obesity, and their associated complications in rodents for DRC investigators and outside users. It also provides training of investigators and trainees in several physiological procedures.

View all literature mentions

Joslin Diabetes Center Advanced Genomics and Genetics Core Facility (tool)

RRID:SCR_009873

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for genetic and genomic analysis, including DNA extraction from blood, access to DNA collections from the Core?s repository, SNP genotyping, and support for gene expression studies based on both high-density oligonucleotide arrays and real-time quantitative PCR.

View all literature mentions

Joslin Diabetes Center Induced Pluripotent Stem Cell Core (tool)

RRID:SCR_015120

Core that maintains a centralized facility for the generation and propagation of reprogrammed iPS cells for use in molecular and cellular pathologies underlying diabetes and its complications.

View all literature mentions

Joslin Diabetes Center Enrichment Core (tool)

RRID:SCR_015094

Six component core which facilitates the exchange of research information and discussions among investigators, fellows and students within the Joslin Diabetes Center, as well as between Joslin Staff and outside researchers with similar interests.

View all literature mentions

B6.129S6-Ccr6tm1(EGFP)Irw/J (tool)

RRID:IMSR_JAX:013061

Mus musculus with name B6.129S6-Ccr6tm1(EGFP)Irw/J from IMSR.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions